There is one clinical trial.
While novel drug discovery and vaccine studies are time taking process, re-purposing old drugs against the COVID-2019 epidemic can help identify treatments, with known pre-clinical, pharmacokinetic, pharmacodynamic, and toxicity profiles, which can rapidly enter Phase 3 or 4 or can be used directly in clinical settings. Immunofree has many of the herbs which have been evaluated by other trials published for Covid-19 treatment. The Immunofree tablet of the test product is an Ayurvedic proprietary medicine and is a combination of polyherbal mixture. The components of this formulation are known for their anti-viral and immunomodulatory effects. Also, Reginmune, owing to its immunomodulatory effect might help in easing the symptoms and decrease the viral load.
Description: This includes overall time it takes for negative covid-19 results, improvement based on a customized questionnaire for fever, cough, body ache, loss of taste or smell, or other similar conditionsMeasure: Time (Days) to clinical improvement from study enrollment Time: Day 0 - Day 10
Description: Being an important part, each patient has to be monitored for oxygen saturation level, and this would help us analyze when a subject enters from Mild to moderate stageMeasure: Proportion of participants in each group with oxygen saturation more than 94% on room air for more than 24h Time: Day 0, Day 5±1 and Day of discharge i.e Day 10±1
Description: D Dimer levels has to be measured to study the D dimer levels of the patient as most researchers claiming covid-19 to be relative to coagulation. This study will help us identity the same.Measure: Value of coagulation indicators Time: Day 0, Day 5±1 and Day of discharge i.e Day 10±1
Description: via ICMR recognized RT-PCR to identify when a patient is coronavirusfreeMeasure: Time to first negative SARS-CoV-2 PCR in NP swab Time: Day 0, Day 5±1 and Day of discharge i.e Day 10±1
Description: To identify how long a patient needs oxygen therapy in certain caseMeasure: Duration of oxygen therapy Time: upto day 10+1
Description: This is considered as a part of pharmacovigilance, as how many people enters moderate to severe case, if anyMeasure: Proportion of participants in each group with need for mechanical ventilation Time: upto day 10+1
Description: most mild cases that becomes asymptomatic are sent back from hospital and treated at home quarantine. this is to identify when a patient becomes asymptomaticMeasure: Duration of hospitalization Time: upto day 10+1
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports